| pubmed-article:10930990 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10930990 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10930990 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:10930990 | lifeskim:mentions | umls-concept:C0030190 | lld:lifeskim |
| pubmed-article:10930990 | lifeskim:mentions | umls-concept:C0087086 | lld:lifeskim |
| pubmed-article:10930990 | lifeskim:mentions | umls-concept:C0086860 | lld:lifeskim |
| pubmed-article:10930990 | lifeskim:mentions | umls-concept:C0380964 | lld:lifeskim |
| pubmed-article:10930990 | lifeskim:mentions | umls-concept:C0598095 | lld:lifeskim |
| pubmed-article:10930990 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:10930990 | pubmed:dateCreated | 2000-9-13 | lld:pubmed |
| pubmed-article:10930990 | pubmed:abstractText | Elevated plasminogen activator inhibitor 1 (PAI-1) levels are associated with venous thromboembolism, although their significance is unclear. PAI-1 levels are influenced by a PAI-1 promoter dimorphism (4G/5G), the 4G allele being associated with increased PAI-1 activity. We investigated whether the 4G allele influenced thrombotic risk by studying 99 symptomatic factor V (FV) Leiden heterozygotes and 99 healthy subjects. The 4G allele was more prevalent among cases than among healthy subjects (chi2 = 8.00, P = 0.005) and the odds ratio (OR) for thrombosis associated with either heterozygosity or homozygosity for the 4G allele was 2.43 (P = 0. 011). We conclude that carriership of the 4G allele was more prevalent in patients who already carried factor V Leiden than in control subjects without factor V Leiden. | lld:pubmed |
| pubmed-article:10930990 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10930990 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10930990 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10930990 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10930990 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10930990 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10930990 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10930990 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:10930990 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:10930990 | pubmed:author | pubmed-author:PeakeI RIR | lld:pubmed |
| pubmed-article:10930990 | pubmed:author | pubmed-author:PrestonF EFE | lld:pubmed |
| pubmed-article:10930990 | pubmed:author | pubmed-author:MakrisMM | lld:pubmed |
| pubmed-article:10930990 | pubmed:author | pubmed-author:DalyM EME | lld:pubmed |
| pubmed-article:10930990 | pubmed:author | pubmed-author:CroftS ASA | lld:pubmed |
| pubmed-article:10930990 | pubmed:author | pubmed-author:VisanjiJ MJM | lld:pubmed |
| pubmed-article:10930990 | pubmed:author | pubmed-author:SeargentJJ | lld:pubmed |
| pubmed-article:10930990 | pubmed:author | pubmed-author:TahriDD | lld:pubmed |
| pubmed-article:10930990 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10930990 | pubmed:volume | 110 | lld:pubmed |
| pubmed-article:10930990 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10930990 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10930990 | pubmed:pagination | 135-8 | lld:pubmed |
| pubmed-article:10930990 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:meshHeading | pubmed-meshheading:10930990... | lld:pubmed |
| pubmed-article:10930990 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10930990 | pubmed:articleTitle | Influence of the -675 4G/5G dimorphism of the plasminogen activator inhibitor 1 promoter on thrombotic risk in patients with factor V Leiden. | lld:pubmed |
| pubmed-article:10930990 | pubmed:affiliation | Division of Molecular and Genetic Medicine, University of Sheffield Faculty of Medicine, Royal Hallamshire Hospital, Sheffield, UK. | lld:pubmed |
| pubmed-article:10930990 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10930990 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
